Blood-Brain Barrier Market By Disease Type (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer), By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing The Permeability Of BBB, Passive Diffusion, Other) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Industry Outlook

The global blood-brain barrier market is projected to reach US$ 5,704.2 million by 2026 from US$ 696.4 million in 2017, growing at a CAGR of 25.0% during the forecast period from 2018 to 2026. The blood-brain barrier (BBB) prevents the free flow of elements from the circulatory system to the cerebrospinal fluid (CSF) or brain, with the blood-brain barrier and the blood-CSF barrier regulating the specific exchange of elements. The key components of the BBB are endothelial cells, capillary basement membrane, astrocytes, and pericytes. Physiologically, water, CO2, oxygen, and lipid-soluble molecules are capable of traveling across the blood-brain barrier; adenosine triphosphate (ATP) produced by the mitochondria carries out the active transport.

Market Synopsis

Alzheimer's and Parkinson's diseases are the most prevalent diseases assisting the growth of the blood-brain barrier market.

Because of the increasing prevalence of these diseases, the introduction of novel diagnostic technology for these diseases, and rising awareness programs organized by governmental and non-governmental organizations, epilepsy, Alzheimer's disease, and Parkinson's disease collectively dominated the market with more than 50% of the market share in 2016. In addition, the increasing geriatric population and rising prevalence of lifestyle-specific CNS disorders are assisting the growth of the global demand for blood-brain barrier technologies. According to Sanofi S.A., epilepsy is the most common neurological disorder, affecting about 20–50 million people worldwide. The disease is more frequent in children than in adults, with the highest incidence occurring in the neonatal period of life and then declining markedly before rising in old age. During the forecast period of 2018 to 2026, Asia Pacific was identified as the fastest-growing blood-brain barrier market due to major driving factors such as the mounting prevalence and incidence of diseases affecting the central nervous system in the geriatric population.

Technological advancements and increased access to modern technology in Asia-Pacific developing countries are driving the market growth.

North America held the largest share of the global blood-brain barrier market in 2016 due to key driving factors such as rising neurological disease prevalence, supportive reimbursement policies, high awareness of early neurological disease diagnosis and treatment, and continuous developments in the field of blood-brain barrier technologies research and development.

According to a research report, an estimated 5.4 million Americans have Alzheimer's disease, and today someone in America develops the disease every 68 seconds. By 2050, it is expected that one new case of Alzheimer's disease will be diagnosed every 33 seconds, or nearly a million new cases per year, and the disease's global prevalence is projected to reach 16 million. During the forecast period of 2018 to 2026, Asia Pacific was identified as the fastest-growing BBB market due to key driving factors such as the increasing prevalence of CNS disorders, rapidly evolving healthcare infrastructure, and rising awareness associated with neurological diseases. Thus, increasing awareness is fueling the rate of diagnosis and increasing the accessibility of patients to modern treatment solutions, especially as observed in developing countries in this region.

Blood-brain barrier technologies are developing rapidly, and their pipeline is very strong.

The blood-brain barrier comprises technologies as follows:

  • SoundCloud (Phase I/IIa)
  • MRI-guided laser ablation combined with doxorubicin, etoposide, and dynamic contrast-enhanced (DCE) imaging MRI (Phase I)
  • MRI (Phase II Completed) + P03277 + Gadobenate Dimeglumine
  • Carboplatin, Mannitol, Melphalan, and Sodium Thiosulfate (Phase I/II)
  • Intra-arterial Cerebral Infusion of Trastuzumab (Phase I)
  • Mannitol 25% + Intra-Arterial Bevacizumab (Phase II)

The most promising products in this list are SonoCloud and P03277 + Gadobenate Dimeglumine. SoundCloud is owned by Cartheera, and Guerbet owns P03277 + Gadobenate Dimeglumine.

Periods of History and Forecast

2016 : Historic year.

2017: Base Year

2018–2026: Forecast Period

The blood-brain barrier market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on the blood-brain barrier market offers in-depth information related to market dynamics and global trends. The report provides a comprehensive summary of the global blood-brain barrier market by segmenting the market based on the type of technology and geography. The objective of publishing this in-depth research report is to assist industry stakeholders in carrying out decisions and strategy implementation in the blood-brain barrier market.

Segmentation by Technology Type (2016-2026; US$ Mn)

  • Bispecific Antibody RMT Approach
    • Ossianic Blood-Brain Barrier Technology (Ossianix)
    • Brain Shuttle Technology (Roche)
    • Other bispecific antibody-based technologies
  • The Trojan Horse Strategy
    • basis (Transcend Technology)
    • LRP Technology (Angiochem)
    • IPRO Technology (Iproteos)
    • ArmaGen Technology Platform (ArmaGen)
    • Vect-Horus Technology Platform (Vect-Horus)
    • G-Technology (BBB Therapeutics)
    • Nano-BBB Technology Platform (Sagetis Biotech)
    • Other Technologies Based on a Trojan Horse Approach
  • BBB Permeability Enhancement
    • SoundCloud Technology (Carrera)
    • SPG Technology (BrainsGate)
    • Other Technologies Based on Increased BBB Permeability
  • Passive Diffusion
    • SciFluor Life Sciences
  • Other non-invasive BBB technologies
    • Smart Molecule Technology (ICBI)
    • Molecular Envelope Technology (Nanomerics)
  • Other Approaches (JCR Pharma, Cyclenium, Cerecor, Lauren Sciences, Protheragen)

Geography Segment (2016-2026; millions of dollars)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia-Pacific (APAC)
    • Japan
    • China
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa (MEA)
    • GCC
    • the remainder of MEA

This report further describes the major qualitative assessment factors, including key market trends, market drivers, and market restraints, to assist in a better understanding of the global blood-brain barrier market. Furthermore, the key players were analyzed graphically based on their product offerings, market strategies, and business strengths. The report also provides an attractive investment proposition based on the extensive geographical research carried out based on PESTEL analysis. Key players profiled in the report include Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., BrainsGate, Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., F. Hoffman-La Roche, Janssen Pharmaceutica NV, and others.

Frequently Asked Questions:

The market for Blood-Brain Barrier Market is expected to reach US$ 5,704.2 Mn by 2026.

The Blood-Brain Barrier Market is expected to see significant CAGR growth over the coming years, at 25.0%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., BrainsGate, Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., F. Hoffman-La Roche, Janssen Pharmaceutica NV are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Jul 2018
Category:  Pharmaceuticals
Report ID:   59234
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support